VST and VST/HCTZ liquisolid tablets inhibit AT1 receptor gene expression (Fig. 4A) via activation of PPARγ and Nrf2 gene expression, as well as by inhibiting MAPK signaling pathways, including P38 and ERK kinases in the L-NAME-induced hypertension model. The gene discussed is PPARG; the disease is hypertensive disorder.